Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Cataliotti

Showing results (11-20 of 97) with videos related to

Pageof 10
Sort By:
American Journal of Physiology. Renal Physiology|April 5, 2003
Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failureHorng H Chen, Margaret M Redfield, Linda J Nordstrom, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|January 4, 2005
Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failureHorng H Chen, Alessandro Cataliotti, John A Schirger, et al.
European Heart Journal|September 4, 2012
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeuticsSarah Mangiafico, Lisa C Costello-Boerrigter, Ingrid A Andersen, et al.
Circulation. Heart Failure|February 24, 2010
Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failureLisa C Costello-Boerrigter, Guido Boerrigter, Alessandro Cataliotti, et al.
Cardiovascular Research|July 9, 2018
Conflicting vascular and metabolic impact of the IL-33/sST2 axisRaffaele Altara, Rana Ghali, Ziad Mallat, et al.
Journal of the American Society of Nephrology : JASN|August 25, 2006
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failureHorng H Chen, Brenda K Huntley, John A Schirger, et al.
European Journal of Heart Failure|March 20, 2003
Leukemia inhibitory factor is augmented in the heart in experimental heart failureMichihisa Jougasaki, Hanna Leskinen, Amy M Larsen, et al.
European Journal of Heart Failure|September 26, 2022
Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta-analysisReza Parvan, Milad Hosseinpour, Yousef Moradi, et al.
Peptides|August 10, 2013
Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosisTomoko Ichiki, Ririko Izumi, Alessandro Cataliotti, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|July 5, 2014
Long-term effects of moderate protein diet on renal function and low-grade inflammation in older adults with type 2 diabetes and chronic kidney diseaseMauro Giordano, Tiziana Ciarambino, Pietro Castellino, et al.
Pageof 10

Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
American Journal of Physiology. Renal Physiology|April 5, 2003
Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failureHorng H Chen, Margaret M Redfield, Linda J Nordstrom, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|January 4, 2005
Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failureHorng H Chen, Alessandro Cataliotti, John A Schirger, et al.
European Heart Journal|September 4, 2012
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeuticsSarah Mangiafico, Lisa C Costello-Boerrigter, Ingrid A Andersen, et al.
Circulation. Heart Failure|February 24, 2010
Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failureLisa C Costello-Boerrigter, Guido Boerrigter, Alessandro Cataliotti, et al.
Cardiovascular Research|July 9, 2018
Conflicting vascular and metabolic impact of the IL-33/sST2 axisRaffaele Altara, Rana Ghali, Ziad Mallat, et al.
Journal of the American Society of Nephrology : JASN|August 25, 2006
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failureHorng H Chen, Brenda K Huntley, John A Schirger, et al.
European Journal of Heart Failure|March 20, 2003
Leukemia inhibitory factor is augmented in the heart in experimental heart failureMichihisa Jougasaki, Hanna Leskinen, Amy M Larsen, et al.
European Journal of Heart Failure|September 26, 2022
Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta-analysisReza Parvan, Milad Hosseinpour, Yousef Moradi, et al.
Peptides|August 10, 2013
Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosisTomoko Ichiki, Ririko Izumi, Alessandro Cataliotti, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|July 5, 2014
Long-term effects of moderate protein diet on renal function and low-grade inflammation in older adults with type 2 diabetes and chronic kidney diseaseMauro Giordano, Tiziana Ciarambino, Pietro Castellino, et al.
Pageof 10